Ecopharmacovigilance is defined as science and activities concerning the detection, assessment, understanding, and prevention of adverse effects or other problems related to the presence of pharmaceuticals in the environment, which affect human and other animal species.

For educational purposes only

Ref: https://www.who.int/publications/i/item/WHO-FWC-WSH-17.05

Ecopharmacovigilance: What Happens to Medicines After We Use Them

Introduction

When a patient swallows a tablet, most people assume the story ends there. The medicine does its job, the patient recovers, and that is that. But the story does not end in the body. A significant portion of every drug dose passes out of the body unchanged or as active metabolites, enters the sewage system, and eventually reaches rivers, lakes, groundwater, and soil. What happens next is the subject of a relatively young but rapidly growing field called ecopharmacovigilance.

Ecopharmacovigilance (EPV) is the science of monitoring, detecting, assessing, and preventing adverse effects of pharmaceutical substances on the environment. It extends the principles of classical pharmacovigilance, which focuses on human safety, outward to ecosystems, wildlife, and the broader biosphere.

Why Pharmaceuticals End Up in the Environment

Medicines enter the environment through several well-documented routes.

Excretion. The human body does not absorb or metabolize every molecule of a drug. Residues are excreted in urine and feces. Wastewater treatment plants, designed primarily to remove organic waste and pathogens, are not equipped to eliminate most pharmaceutical compounds. Studies in Europe, North America, and Asia have consistently found measurable concentrations of analgesics, antibiotics, hormones, antidepressants, and antihypertensives in treated effluent.

Improper disposal. Patients who flush unused medicines down the toilet or throw them in household waste contribute directly to environmental contamination. This is a behavioral problem as much as a regulatory one.

Agricultural runoff. Veterinary medicines, particularly antibiotics and antiparasitic agents used in livestock farming, enter the soil and surface water through animal waste applied as fertilizer or through direct field drainage.

Manufacturing discharges. Pharmaceutical manufacturing facilities, especially in countries with weak effluent controls, have been documented releasing high concentrations of active pharmaceutical ingredients (APIs) directly into waterways. A landmark study near Hyderabad, India, found antibiotic concentrations in a local river near a bulk drug manufacturing cluster that exceeded therapeutic doses for humans.

What Environmental Contamination Does

The ecological consequences of pharmaceutical pollution are not theoretical. They are observed, documented, and in some cases, irreversible.

Endocrine disruption in fish. Synthetic estrogens, particularly 17-alpha-ethinylestradiol from oral contraceptives, cause feminization of male fish at concentrations as low as a few nanograms per liter. In the early 2000s, studies in UK rivers showed that a high proportion of male roach living downstream from sewage treatment outlets were producing vitellogenin, an egg yolk protein normally found only in females. Reproductive failure in fish populations followed.

Antimicrobial resistance (AMR). This is perhaps the most serious public health consequence of pharmaceutical environmental contamination. When antibiotics are present in water and soil at sub-inhibitory concentrations, they do not kill bacteria. Instead, they create precisely the selective pressure needed to favor resistant strains. Environmental reservoirs of resistance genes, known as the resistome, then transfer these genes to human pathogens through horizontal gene transfer. EPV and AMR surveillance are now inseparable disciplines.

Behavioral changes in wildlife. Psychoactive drugs in water at trace levels have been shown to alter the behavior of fish and amphibians. Antidepressants affect feeding behavior, boldness, and reproductive activity in several aquatic species. These are not headline-grabbing acute toxicities. They are subtle, chronic shifts in animal behavior that accumulate quietly across generations.

Effects on plants and soil microbiota. Pharmaceuticals reaching agricultural soil through irrigation or biosolid application can be taken up by crop plants or alter the microbial communities that sustain soil fertility. Research on fluoroquinolone antibiotics has demonstrated disruption of nitrifying bacteria in soil, with downstream consequences for nitrogen cycling.

Core Concepts in EPV

Environmental Risk Assessment (ERA)

Regulatory agencies require pharmaceutical manufacturers to conduct an Environmental Risk Assessment before a new drug is approved. The ERA estimates the predicted environmental concentration (PEC) of a substance and compares it with the predicted no-effect concentration (PNEC). A PEC/PNEC ratio greater than 1 triggers concern and requires further investigation.

ERA, however, has significant limitations. It typically evaluates single compounds in isolation, while real environments receive mixtures of hundreds of pharmaceuticals simultaneously. The combined effect of these mixtures, even when each individual compound is below its PNEC, can be substantial. This is called the mixture toxicity problem, and it remains one of the central scientific challenges in EPV.

Persistence, Bioaccumulation, and Toxicity (PBT)

Regulatory frameworks assess APIs for their PBT profile. A compound is flagged as a concern if it persists in the environment without degrading, accumulates in the fatty tissues of organisms, and is toxic at low concentrations. Diclofenac, a widely used anti-inflammatory drug, is a useful case study. It caused catastrophic declines in vulture populations across South Asia after the birds consumed carcasses of livestock treated with the drug. The Indian subcontinent lost over 95% of its vulture population within a decade, with serious downstream consequences for public health, since vultures are a critical part of the carcass disposal system.

Green Pharmacy and Sustainable Design

One proactive approach within EPV is green pharmacy, or designing drugs with their environmental fate in mind from the outset. This means selecting APIs that degrade readily under environmental conditions, optimizing dosing to reduce excretion loads, and developing formulations that release less unchanged drug. This requires collaboration between medicinal chemists, toxicologists, and environmental scientists, a cross-disciplinary integration that the pharmaceutical industry has been slow to adopt but is increasingly being pushed toward by regulation.

Post-Market Environmental Monitoring

Just as post-market surveillance in classical pharmacovigilance involves ongoing collection of adverse drug reaction reports after a medicine is approved, EPV calls for ongoing environmental monitoring after a drug enters widespread use. This includes monitoring surface water, groundwater, sediment, and biota for pharmaceutical residues and for biological signals such as changes in species composition, reproductive abnormalities, and shifts in microbial ecology. Most national pharmacovigilance systems do not yet have formal mechanisms for this kind of monitoring. Building those systems is a current priority in the field.

Regulatory Landscape

The European Medicines Agency (EMA) mandates ERA for all new human medicines. The US Food and Drug Administration (FDA) requires categorical exclusions or full ERA depending on the expected environmental concentration. However, medicines approved before current ERA requirements came into force, including many high-volume drugs that have been in use for decades, were never assessed for environmental impact.

The WHO has recognized pharmaceutical pollution as a global public health issue. The Global Action Plan on AMR explicitly names the environment as a reservoir and amplifier of resistance. Several international initiatives, including the OECD's work on pharmaceuticals in the environment and the UN Environment Programme's Freshwater programme, are working toward harmonized global monitoring standards.

In India, the Central Pollution Control Board (CPCB) and the Ministry of Environment, Forest and Climate Change have issued guidelines on effluent standards for pharmaceutical manufacturing. Implementation and enforcement, however, remain inconsistent.

The Role of Pharmacovigilance Professionals in EPV

Classical pharmacovigilance professionals are well positioned to contribute to EPV, because the methodological toolkit overlaps substantially. Signal detection, causality assessment, benefit-risk evaluation, and communication with regulatory agencies are competencies that transfer directly.

What EPV adds is a shift in the unit of observation. In classical PV, the patient is the subject. In EPV, the subject may be a river ecosystem, a population of birds, a soil microbiome, or the global gene pool of bacteria. The adverse event may not manifest for years or decades, may affect organisms that have never taken the drug in question, and may be irreversible in ways that adverse drug reactions in humans are not.

This demands a broader scientific literacy, an ability to read and critically appraise ecotoxicology studies, understand ecological endpoints, and engage with environmental science literature alongside regulatory pharmacology.

Case Studies Worth Knowing

Diclofenac and South Asian vultures. Covered above. This is the defining case study in EPV and should be known in detail by every pharmacovigilance professional.

Ethinylestradiol and fish feminization. Documented extensively in UK rivers in the late 1990s and early 2000s. Led directly to calls for improved ERA requirements in Europe.

Antibiotic manufacturing pollution in Patancheru, India. A 2007 study published in the journal Environmental Health Perspectives documented ciprofloxacin concentrations in a river near bulk drug manufacturers at levels sufficient to treat a person. This drove international attention to the supply chain dimension of pharmaceutical environmental contamination.

Fluoxetine and aquatic invertebrates. Multiple studies have shown that fluoxetine (Prozac) at environmental concentrations affects serotonin signaling in invertebrates, altering reproductive behavior and development in species that were never the intended therapeutic target.

Key Takeaways

Pharmaceuticals are biologically active by design. That activity does not stop at the sewage treatment plant. The same pharmacological potency that makes a drug therapeutically effective makes it ecologically disruptive when it reaches an ecosystem at concentrations it was never intended to occupy.

EPV is not a niche academic discipline. It sits at the intersection of drug safety, public health, environmental science, and regulatory policy. As the global pharmaceutical burden on ecosystems grows alongside rising drug consumption, aging populations, and increasing veterinary use, the professionals who understand both pharmacovigilance methodology and environmental risk will be among the most relevant people in the room.

The field is not yet mature. Monitoring systems are incomplete. Regulatory frameworks have gaps. The science of mixture toxicity is still developing. That makes it a field with genuine intellectual frontier, where careful observation, methodological rigor, and cross-disciplinary thinking can still produce knowledge that changes policy and protects ecosystems that cannot advocate for themselves.

Discussion Questions

1. A new non-steroidal anti-inflammatory drug (NSAID) is under regulatory review. The ERA shows a PEC/PNEC ratio of 0.8 for aquatic organisms. Should this be considered safe? What additional factors would you want to evaluate?

2. Antibiotic resistance genes have been found in a river located 200 km from the nearest hospital or pharmaceutical manufacturer. What are the possible sources, and how would you design a surveillance study to identify them?

3. Diclofenac was withdrawn from veterinary use in India in 2006 following the vulture collapse. What lessons does this case offer for how post-market environmental monitoring should be structured for high-volume drugs?

4. A pharmaceutical company proposes to market a highly effective but environmentally persistent antifungal agent. How should regulators weigh therapeutic benefit against ecological risk?

5. Patients routinely flush unused medicines. What behavioral, regulatory, and infrastructural interventions would most effectively reduce pharmaceutical input to the sewage system?